Results 171 to 180 of about 4,104 (188)
Some of the next articles are maybe not open access.

SAT-071 Long-Term Effect of Subcutaneous Pasireotide on Clinical and Quality of Life Endpoints in Patients with Cushing's Disease: Results from a Non-interventional Study

Journal of the Endocrine Society
J. Bertherat: Consulting Fee; Self; Atterocor, Shire, HRA Pharma Rare Diseases, Novartis Pharmaceuticals, Corcept Therapeutics, Recordati Rare Diseases. Grant Recipient; Self; Novartis Pharmaceuticals, Pfizer, Inc., HRA Pharmaceuticals. S. Cannavò: None.
J. Bertherat   +11 more
semanticscholar   +1 more source

Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs

Journal of Endocrinological Investigation, 2023
G. Corica   +11 more
semanticscholar   +1 more source

De-escalation treatment with pasireotide for acromegaly: a long-term experience

Endocrine, 2023
A. Giampietro   +5 more
semanticscholar   +1 more source

Efficacy and safety of pasireotide treatment in acromegaly: A systematic review and single arm meta-analysis

Pituitary
Turkan Aliyeva   +4 more
semanticscholar   +1 more source

Current role of pasireotide in the treatment of acromegaly.

Best practice & research. Clinical endocrinology & metabolism
S. Bhat, Roberto Salvatori
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy